Dubai Telegraph - Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

EUR -
AED 4.23704
AFN 74.992126
ALL 91.801223
AMD 418.589514
ANG 2.065583
AOA 1059.116704
ARS 1738.621483
AUD 1.617669
AWG 2.078141
AZN 1.968959
BAM 1.956261
BBD 2.324357
BDT 142.092849
BGN 1.942222
BHD 0.435089
BIF 3451.727898
BMD 1.153722
BND 1.46954
BOB 12.689043
BRL 5.926321
BSD 1.154077
BTN 110.738721
BWP 15.652619
BYN 3.50461
BYR 22612.94572
BZD 2.320996
CAD 1.608277
CDF 2667.982172
CHF 0.944904
CLF 0.027859
CLP 1100.039261
CNY 7.743146
CNH 7.739072
COP 3608.80693
CRC 516.219341
CUC 1.153722
CUP 30.573626
CVE 110.290975
CZK 24.311341
DJF 205.509291
DKK 7.475476
DOP 68.125749
DZD 154.371425
EGP 60.017416
ERN 17.305826
ETB 188.50091
FJD 2.553129
FKP 0.855988
GBP 0.857348
GEL 2.991968
GGP 0.855988
GHS 13.254179
GIP 0.855988
GMD 84.802591
GNF 10147.34589
GTQ 8.810113
GYD 241.447911
HKD 9.050757
HNL 30.974161
HRK 7.534723
HTG 150.836178
HUF 364.454969
IDR 20357.419757
ILS 3.497219
IMP 0.855988
INR 110.61855
IQD 1511.849513
IRR 1585905.877266
ISK 139.796407
JEP 0.855988
JMD 182.122893
JOD 0.818056
JPY 178.861126
KES 149.476721
KGS 100.892849
KHR 4673.060078
KMF 492.639538
KPW 1038.349915
KRW 1576.595359
KWD 0.355843
KYD 0.961722
KZT 513.145287
LAK 25834.524646
LBP 103345.387414
LKR 382.510087
LRD 200.226289
LSL 18.788806
LTL 3.406641
LVL 0.697874
LYD 7.329726
MAD 10.882663
MDL 20.120652
MGA 4990.067113
MKD 61.544495
MMK 2422.382471
MNT 4147.716277
MOP 9.324894
MRU 46.207883
MUR 54.478572
MVR 17.766827
MWK 2001.179983
MXN 19.772575
MYR 4.666579
MZN 73.734259
NAD 18.788644
NGN 1529.708151
NIO 42.469818
NOK 10.790777
NPR 177.188499
NZD 2.001794
OMR 0.443614
PAB 1.154047
PEN 3.871795
PGK 5.218229
PHP 72.367772
PKR 319.872935
PLN 4.347033
PYG 6828.608249
QAR 4.195388
RON 5.259243
RSD 117.357749
RUB 97.405102
RWF 1702.793656
SAR 4.330004
SBD 9.271597
SCR 15.755618
SDG 693.953467
SEK 11.288002
SGD 1.468959
SHP 0.856321
SLE 28.427578
SLL 24192.958249
SOS 659.552477
SRD 43.553301
STD 23879.710257
STN 24.505665
SVC 10.098335
SYP 15000.690102
SZL 18.786506
THB 38.354318
TJS 10.644262
TMT 4.049563
TND 3.378696
TOP 2.777885
TRY 56.124984
TTD 7.824605
TWD 36.692984
TZS 3052.31852
UAH 51.466821
UGX 4518.064078
USD 1.153722
UYU 46.430935
UZS 13606.204485
VES 970.492275
VND 29995.034148
VUV 136.32031
WST 3.157429
XAF 655.957
XAG 0.017803
XAU 0.000265
XCD 3.117991
XCG 2.079881
XDR 0.815741
XOF 655.957
XPF 119.331742
YER 272.853304
ZAR 18.765744
ZMK 10384.877521
ZMW 22.648236
ZWL 371.497923
SSP 6524.623405
MXV 2.241941
  • RIO

    0.4300

    97.68

    +0.44%

  • BTI

    0.3200

    56.84

    +0.56%

  • CMSC

    -0.1000

    20.32

    -0.49%

  • GSK

    0.6700

    50.65

    +1.32%

  • RBGPF

    0.0000

    69.99

    0%

  • CMSD

    0.1275

    20.209

    +0.63%

  • NGG

    1.4880

    76.398

    +1.95%

  • BCC

    0.1650

    76.01

    +0.22%

  • RELX

    -0.0300

    34.18

    -0.09%

  • BCE

    -0.1760

    22.719

    -0.77%

  • JRI

    0.0550

    11.735

    +0.47%

  • RYCEF

    0.2600

    19.3

    +1.35%

  • VOD

    -0.1850

    17.495

    -1.06%

  • AZN

    3.2650

    165.075

    +1.98%

  • BP

    -0.6900

    46.25

    -1.49%

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

  • Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations

  • Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization

  • Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks

Text size:

TAMPA, FL / ACCESS Newswire / April 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech's wholly owned subsidiary, Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs.

The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations' technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx's digital hub, the combined platform is positioned to streamline the prescription journey from intake through fulfillment.

Prashant Patel, Chief Executive Officer of Wellgistics Health, commented, "This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies. By combining KareRx's provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively."

The joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than 200,000 patient lives based on third-party internal estimates.

Mital Panera, Founder and Chief Executive Officer of KareRx, added, "KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics' technology stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders and facilitate access to therapies across participating networks."

The collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence, and deliver enhanced visibility into patient access and program performance.

The joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

About Kare PharmTech, LLC

Kare Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical 'lite' branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market unique specialty pharmaceutical 'lite' products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Wellgistics Media & Investor Contact
Media: [email protected]
Investor Relations: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

R.El-Zarouni--DT